Business
CollPlant Announces Corporate Name Change to CollPlant Biotechnologies to Better Reflect Its Business
REHOVOT, Israel, June 20, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative medicine company, announced today that its corporate
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"REHOVOT, Israel, June 20, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the \"Company\"), a regenerative medicine company, announced today that its corporate name has changed from \"CollPlant Holdings Ltd.\" to \"CollPlant Biotechnologies Ltd.\" effective on the opening of trading on June 21, 2019. The Company's ADSs will continue trading on the Nasdaq Capital Market under the same ticker symbol \"CLGN\".\n\"This corporate rebranding, including our name change and new logo, effectively reflects the strategic shift in our business, and the high value opportunities we are pursuing in the field of regenerative medicine,\" said Yehiel Tal, CollPlant Biotechnologies CEO. \"Over the last two years, we have taken strategic actions transitioning the Company to focus on our medical aesthetics and 3D bioprinting platform technologies. The path ahead is clear and we look forward to providing further updates as we continue to execute upon our strategy.\"\nCollPlant has made significant progress over the past two years in advancing its rhCollagen technology including signing a commercialization agreement for 3D bioprinted lung transplants with United Therapeutics (UTHR); establishing a new rhCollagen and BioInk production facility; launching a new HQ and R&D center; developing a new dermal filler product line for the medical aesthetics market; and listing the Company's ADSs on the Nasdaq.\nAbout CollPlant\nCollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, medical aesthetics, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.\nOur products address indications for the diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. We recently entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans. CollPlant's unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a w...